← All trials
NCT07065357
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2025
- Primary completion
- Aug 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Jul 15, 2025
- Last posted
- Aug 24, 2025
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The University of Hong KongLead sponsor
- The University of Hong KongSponsor investigator
- The University of Hong KongOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.